5 - Contents

6-7 NEWS
Sanofi to acquire Inhibrx in deal worth $2.2bn; Biogen to discontinue Alzheimer’s drug Aduhelm

8-9 NEWS
Roche’s Tecentriq approved by EC; Novo Nordisk’s once-weekly IcoSema shows promise in type 2 diabetes

10-11 DERMATOLOGY NEWS
Almirall and Microsoft partner on digital transformation; BMS’ Opdualag recommended by NICE for melanoma

12 DARWIN'S MEDICINE
Commercial excellence – big truths, small spaces

13 POLICY AND PUBLIC HEALTH
Fool me once – the impact of social media

14 AI AND OVER-DIGITALISATION
The possibility of errors and the need to be cautious

15 INNOVATIVE IMPACT BLOG
The pharma trailblazer's skill set: forged in rare diseases

16-17 RARE DISEASES – IMPROVING PATIENT ACCESS
Despite significant strides, many rare disease patients have no licensed treatment options and face high levels of unmet need

20-22 AMR – INCENTIVISING INNOVATION IN ANTIBIOTICS
Why current intellectual property and regulatory data exclusivity systems are failing to stimulate innovation in the field of antibiotics and antimicrobials

24-25 PIPELINE PUZZLE – US INFLATION REDUCTION ACT
Navigating the US Act’s impact on portfolio, drug development and product launch strategy

26-27 MARKING INTERNATIONAL DAY
OF WOMEN AND GIRLS IN SCIENCE
With February marking the International Day of Women and Girls in Science, PME talks to Emma Banks, CEO of ramarketing, to find out more about her career

30-31 LANDMARK PROJECT BOOSTS SEX AND GENDER EQUITY IN UK MEDICAL RESEARCH PROJECT
PME talks to Kate Womersley about MESSAGE, a landmark UK DE&I project, and how major funders are committing to only approving research projects that treat men and women fairly

32-33 ACHIEVING PATIENTGUIDED
DRUG DEVELOPMENT: KEEPING THE
PATIENT EXPERIENCE A PRIORITY
Even a comprehensive approach does not provide the full picture without involvement from the ultimate end users – the patients themselves

37 HEALTHCARE COMMS
Evoke unveils simplified brand and structure; Stirred announces Stirred Well, a new wellness offering

FEBRUARY 2024